Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge

This publication has 83 references indexed in Scilit:

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
  New England Journal of Medicine, 2013
• Nivolumab plus Ipilimumab in Advanced Melanoma
  New England Journal of Medicine, 2013
• Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
  Cancer Investigation, 2013
• Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
  New England Journal of Medicine, 2013
• Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
  Journal of Translational Medicine, 2013
• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
  New England Journal of Medicine, 2011
• Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
  Rheumatology, 2010
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
  Clinical Cancer Research, 2009
• Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
  Journal of Immunotherapy, 2008
• PD-1 and Its Ligands in Tolerance and Immunity
  Annual Review of Immunology, 2008